Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake.

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Eikon is building a high-profile line of potential drugs. Its portfolio is led by EIK-1001, which is just rolling out a ...